In diabetic subjects, the incretin effect is reduced or absent; GLP1-RAs are able to restore this balance and are therefore widely used for the treatment of T2DM due to their ability to lower glucose and cardiometabolic risk, with a low risk of hypoglycemia [161]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.